Arcus grabs US rights to a WuXi-built PD-1 as second wave of checkpoints builds
West Coast upstart Arcus Biosciences has bagged its very own PD-1 antibody to take into the clinic with its immuno-oncology pipeline drugs.
Arcus turned to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
